Table 1.

Vaccines for TGEV and PEDV

Virus	Region/country	Vaccines in development	Commercial vaccines
TGEV	North America	Recombinant proteins expressed in baculovirus, yeast, and plants; live attenuated vaccine; DNA vaccine	Live attenuated vaccines (mono, bi-, and trivalent for TGEV, rotavirus, and E. coli)
	Europe	Recombinant proteins expressed in baculovirus, yeast, and plants; live attenuated vaccine; DNA vaccine	Live attenuated vaccines (mono, bi-, and trivalent for TGEV, rotavirus, and E. coli)
	Asia	Recombinant proteins expressed in baculovirus, yeast, and plants; live attenuated vaccine	Inactivated vaccines (mono, bi-, and trivalent for TGEV, rotavirus, PEDV and/or E. coli); live attenuated trivalent for TGEV, PEDV, and porcine (China)
PEDV	North America	Recombinant proteins expressed in yeast and baculovirus; DNA vaccine; infectious clone for live attenuated vaccine;	Inactivated vaccine; recombinant alphavirus-based vaccine
	Europe	DNA vaccine	Inactivated vaccine
	Asia	Recombinant vaccines expressed in baculovirus, yeast, plants, Lactobaccilus casei, Salmonella typhimurium and others	Inactivated bivalent TGEV and PEDV vaccine (China, PEDV strain CV777); live attenuated trivalent TGEV, PEDV, and porcine rotavirus (China, PEDV strain CV777); live attenuated vaccines (Japan, PEDV strain 83P-5; South Korea, PEDV strains SM98-1 and DR-13; Philippines, PEDV strain DR-13); inactivated vaccine (South Korea, PEDV strain SM98-1)

Note: Gerdts, V., Zakhartchouk, A., 2017. Vaccines for porcine epidemic diarrhea virus and other swine coronaviruses. Veterinary Microbiology 206, 45–51, with permission.